Vivek Ramaswamy is founder and Chief Executive Officer of Roivant Sciences. The Roivant family of companies includes multiple wholly-owned or majority-owned biopharmaceutical subsidiaries, each focused on a different disease area. With its affiliates, Roivant has raised over $2.8 billion in capital to date to fund clinical programs and pursue adjacent business opportunities in healthcare.

Prior to founding Roivant, Mr. Ramaswamy was an investor in the biotechnology sector. He currently serves as a member of the board of directors of Roivant Sciences and as chairman of the boards of directors of Axovant Sciences, Myovant Sciences, and Arbutus Biopharma Corporation. He received an A.B. summa cum laude in biology from Harvard College and a J.D. from Yale Law School.